Abstract
Purpose
Radiotherapy-induced trismus is present in up to 40% of patients treated radiotherapeutically for head and neck cancer (HNC) and impacts health-related quality of life (HRQL) negatively. This prospective study aimed to investigate the development of trismus and its influence on HRQL and trismus-related symptoms in HNC patients for up to 5 years post-radiotherapy completion as no such follow-up studies exist.
Methods
Patients (n = 211) were followed prospectively from pre-radiotherapy to 12 and 60 months post-radiotherapy. At each follow-up, maximum interincisal opening (MIO) was measured, and patients filled in the European Organization for Treatment of Cancer Quality-of-Life Questionnaire Core-30 (EORTC QLQ-C30), Head and Neck-35 (EORTC QLQ-HN35), and Gothenburg Trismus Questionnaire (GTQ). Trismus was defined as an MIO ≤ 35 mm.
Results
At 1 year post-radiotherapy, a total of 27% met the trismus criterion, and at 5 years post-radiotherapy, the corresponding figure was 28%. Patients in the trismus group scored significantly worse compared to the patients without trismus on 8/15 domains at 1 year post-radiotherapy on EORTC QLQ-C30, further worsening in 11/15 domains at 5 years post-radiotherapy. Similar results were found for EORTC QLQ-HN35. Patients with trismus reported more trismus-related symptoms according to the GTQ at both timepoints compared to those without trismus.
Conclusion
This study highlights that HNC patients suffering from radiotherapy-induced trismus report poorer HRQL and more trismus-specific symptoms compared to patients without trismus. These differences persist and increase up to at least 5 years following treatment completion. Hence, our results highlight that radiotherapy-induced trismus affects long-term HRQL, jaw symptoms, and pain, further stressing the need for early and structured intervention.
Keywords: Trismus, Radiotherapy, Health-related quality of life, Mouth opening ability, Head and neck cancer
Introduction
Over the past 30 years, the epidemiology of head and neck cancer (HNC) has changed, with a decline seen in tobacco- and alcohol-related HNC and an increase in human papillomavirus (HPV)-related HNC. In Sweden, there has been a steady increase in the annual incidence of HNC with a 38% increase in new cases reported by the National Quality Registries in Swedish Health Care between 2008 and 2019 [1].
Tumors of HNC are most commonly treated surgically or radiotherapeutically with or without the addition of chemotherapy [2]. In general, patients with HPV-related HNC are younger and have a better overall survival prognosis than those with other HNC [3, 4]. As the survival rates increase for patients treated for HNC, an increased interest among clinicians and researchers has developed to optimize long-term function and improve health-related quality of life (HRQL) among these affected individuals. One burdensome, potentially long-term complication that may occur in up to 40% of patients after oncologic treatment of HNC is trismus, or restricted mouth opening [5–7]. The most widely used criterion for trismus is that of Dijkstra et al. [8], which defines trismus as a maximum interincisal opening (MIO) ≤ 35 mm.
Previous studies focusing on post-radiotherapy (RT) trismus have demonstrated that trismus impacts HRQL negatively and may cause pain as well as interference with normal daily activities such as speaking or eating [9–12]. As no follow-up studies regarding HRQL beyond 3 years post-RT completion exist, it is yet unclear whether these negative effects persist, which exposes an important knowledge gap in the literature.
Hence, this prospective observational cohort study aims to investigate the development of trismus and its influence on HRQL and trismus-related symptoms, comparing HNC patients who develop postradiation trismus to those who do not for up to 5 years post-RT.
Materials and methods
Study participants and design
Patients were invited to participate in this study in connection with the weekly multidisciplinary tumor board meetings for all new cases of diagnosed HNC in the region of West Sweden at Sahlgrenska University Hospital in Gothenburg, between 2007 and 2012. The Sahlgrenska University Hospital is one of the major university hospitals in Northern Europe and the specialized center for HNC treatment for the Swedish county of Vastra Gotaland, populated by 1.7 million. Inclusion criteria were 18 years of age or older, receiving curatively intended RT, and cancer sites in the oral cavity, oropharynx, nasopharynx, salivary glands, paranasal sinuses, or cervical carcinoma of unknown primary (CCUP). Exclusion criteria included pre-treatment MIO of ≤ 35 mm, recurrent disease, surgical treatment alone, and insufficient cognitive abilities and Swedish language competency to independently complete the questionnaires and partake in examinations. Patients were followed prior to RT (baseline) and at 12 and 60 months post-RT. At each follow-up, MIO was measured, and the patients filled in patient-reported outcome instruments related to HRQL and trismus-specific symptoms, as described below. The Adult Comorbidity Index 27 (ACE27) and Karnofsky Performance Status Scale were filled in at baseline only [13, 14].
Oncologic treatment
Tumors were classified according to the global standard, the TNM-staging system by the International Union Against Cancer (UICC), which includes tumor size (T), regional lymph nodes involvement (N), and distant metastasis (M) [15]. Curatively intended RT was administered according to regional guidelines. During 2007–2009, external RT was generally administered through accelerated hyperfractionated therapy as 1.7 Gray (Gy) per fraction 5 days per week, totaling 64.6 Gy. During 2010–2012, the external RT was administered through accelerated fractioning as 2 Gy per fraction one or two times per day for 5 days per week with a total of six treatments per week, totaling 68 Gy. Induction (cisplatin and 5-fluoruracil) or concomitant (weekly cisplatin) chemotherapy was added to the RT for patients with stage III to IV disease in accordance with local treatment standards (n = 141).
Surgery was performed with post-operative RT with or without the addition of chemotherapy for some tumor sites. Oral tumors stage III–IV were treated with surgery, including diagnostic and therapeutic neck dissections and radiotherapy. If the tumor was assessed to be unresectable, the patient received chemoradiotherapy only.
Furthermore, primary site tumors were removed surgically, including neck dissection, followed by post-operative RT also if located in the salivary glands and sinonasal cancers. Neck dissections were also performed before administering non-surgical oncologic treatment in selected cases of those diagnosed with CCUP, depending on the status of their nodal metastasis. Non-surgical treatment was clinical practice for oropharyngeal and nasopharyngeal tumors.
Outcome measures
Maximum interincisal opening (MIO)
MIO was measured in millimeters with a ruler as the maximum distance between the upper and lower incisors at all three timepoints. The cut-off point defining trismus was an MIO of ≤ 35 mm [8]. Edentulous patients measured MIO with the dental prosthesis in place.
The European Organization for Research and Treatment of Cancer
The European Organization for Research and Treatment of Cancer Quality-of-Life Questionnaires (EORTC QLQ) were used to measure HRQL at all timepoints. Firstly, the EORTC QLQ Core-30 (QLQ-C30), which is a cancer-specific instrument, was utilized [16]. In addition to this, the complementary head and neck disease-specific module EORTC QLQ-HN35 was added for depth regarding HNC-specific symptoms [17].
The EORTC QLQ-C30 consists of five function scales, a global quality of life scale, three symptom scales, and six single items, totaling 30 items that describe the patients’ symptoms and functional level during the last week. The EORTC QLQ-HN35 consists of 35 items addressing symptoms specific to HNC and its treatments. Scores range from 0 to 100, where higher scores represent better function in the functioning domains and a higher global quality of life, whereas higher scores in the symptom domains equate to a higher symptom burden [18].
Gothenburg Trismus Questionnaire (GTQ)
The GTQ is the first comprehensive trismus-specific questionnaire and was developed as a complement to the objective measure of MIO. The GTQ is composed of three domains containing 13 items: jaw-related problems (six items), eating limitations (four items), and muscular tension (three items). Additionally, there are eight single items. The scores of the domains and single items range from 0 to 100, where a higher score indicates more symptoms and lower scores represent less symptoms [19].
Statistical analysis
For categorical variables, number and percentages are presented. Standard deviation is presented for relevant variables related to sociodemographic data in Table 1. Continuous variables are presented using mean and 95% confidence interval. For comparisons between groups, Fischer’s exact test was used for dichotomous variables, Mantel-Haenszel chi-square test for ordered categorical variables, Mann–Whitney U test for continuous variables, and chi-square test for non-ordered categorical variables. All tests were two-sided and conducted at a 5% significance level. SAS version 9.4 was used for analyses.
Table 1.
Sociodemographic data at baseline and 5-year follow-up (mean, n, SD, 95% CI, %)
| Baseline (n = 211) | 5 years post-RT (n = 129) | P value a | ||
|---|---|---|---|---|
| Trismus (n = 36) | No trismus (n = 93) | |||
| Mean (range; SD) 95% CI | Mean (range; SD) 95% CI | Mean (range; SD) 95% CI | ||
| Age | 61.0 (29–86; 10.2) 60–62 | 59.3 (29–80; 9.6) 59–61 | 59.6 (31–80; 9.8) 59–62 | 0.88 |
| Karnofsky Performance Scale b | 97.5 (60–100; 6.6) 97–98 | 98.3 (70–100; 6.1) 97–99 | 98.8 (70–100; 4.6) 98–99 | 0.86 |
| n (%) | n (%) | n (%) | ||
| Sex | ||||
| Male | 157 (74) | 26 (72) | 66 (71) | 1.00 |
| Female | 54 (26) | 10 (28) | 27 (29) | |
| Living alone | ||||
| Yes | 58 (27) | 12 (33) | 18 (19) | 0.18 |
| No | 153 (73) | 24 (67) | 75 (81) | |
| Educational years | ||||
| 6-9 years | 58 (27) | 6 (17) | 24 (26) | 0.69 |
| 9-12 years | 99 (47) | 20 (55) | 40 (43) | |
| >12 years | 54 (26) | 10 (28) | 29 (31) | |
| Employment status | ||||
| Full time | 98 (46) | 19 (53) | 49 (53) | 0.96 |
| Part time | 16 (8) | 3 (8) | 8 (8) | |
| Unemployed | 8 (4) | 1 (3) | 2 (2) | |
| Old age pensioner | 70 (33) | 8 (22) | 25 (27) | |
| Early retiree | 19 (9) | 5 (14) | 9 (10) | |
| Dental status | ||||
| Upper prosthesis | 2 (1) | 0 (0) | 0 (0) | 0.87 |
| Lower prosthesis | 1 (1) | 0 (0) | 1 (1) | |
| Both upper+lower prosthesis | 4 (2) | 1 (3) | 0 (0) | |
| Own teeth | 204 (96) | 35 (97) | 92 (99) | |
| Smoking | ||||
| Yes | 49 (23) | 28 (78) | 72 (77) | 1.00 |
| No | 162 (77) | 8 (22) | 21 (23) | |
| BMI mean (range; SD), 95% CI | 26.7 (17–46; 4.4) 26–27 | 27.3 (22–40; 4.1) 27-28 | 26.5 (17–37; 3.7) 26–28 | 0.80 |
| BMI group | ||||
| < 18.5 | 3 (2) | 0 (0) | 2 (2) | 1.00 |
| 18.5–25 | 68 (32) | 10 (28) | 27 (29) | |
| > 25 | 139 (66) | 26 (72) | 64 (69) | |
| Missing = 1 | ||||
| Cancer stage | ||||
| I | 8 (4) | 2 (6) | 9 (10) | 0.69 |
| II | 36 (17) | 7 (19) | 22 (23) | |
| III | 49 (23) | 10 (28) | 14 (15) | |
| IV | 118 (56) | 17 (47) | 48 (52) | |
| Tumor site | ||||
| Oral cavity | 34 (16) | 7 (19) | 8 (9) | 0.14 |
| Oropharynx | 132 (62) | 19 (53) | 65 (69) | |
| Salivary gland | 8 (4) | 1 (3) | 4 (4) | |
| Nasopharynx/sinuses | 16 (8) | 2 (6) | 8 (9) | |
| CCUP | 21 (10) | 7 (19) | 8 (9) | |
| Cancer treatment | ||||
| RT only | 45 (21) | 6 (17) | 15 (16) | 0.07 |
| Surgery + [C]RT | 35 (17) | 13 (36) | 15 (16) | |
| CRT | 131 (62) | 17 (47) | 63 (68) | |
| ACE27 | ||||
| No comorbidity | 92 (44) | 21 (58) | 43 (46) | 0.89 |
| Mild comorbidity | 76 (36) | 8 (22) | 36 (39) | |
| Moderate comorbidity | 35 (16) | 5 (14) | 14 (15) | |
| Severe comorbidity | 8 (4) | 2 (6) | 0 (0) | |
Abbreviations: ACE27 Adult Comorbidity Evaluation 27, BMI body mass index, CCUP cervical carcinoma of unknown primary, CRT chemoradiotherapy, RT radiotherapy, SD standard deviation. aP values comparing data between the trismus versus no trismus groups. bRange from 0 to 100 equals perfect health
Ethical considerations
The study was conducted according to the Declaration of Helsinki and was approved by the Regional Ethic Review Board in Gothenburg, Sweden. All participants gave their written informed consent before study inclusion.
Results
Sociodemographic and clinical data
A total of 211 patients were included. The baseline sociodemographic and clinical characteristics can be found in Table 1. At the 12-month follow-up, 180 (85%) patients remained enrolled in the study and at the 5-year follow-up the corresponding number was 129 (61%). Reasons for drop-out at 5 years post-RT were tumor recurrence (n=39), poor general health (n=4), death due to unknown cause (n=13) and unknown (n=26). The 129 patients completing the study had at baseline significantly higher Karnofsky scores, i.e. better performance status (98.7 vs 95.6, p<0.001), less comorbidity as measured by ACE27 (p=0.006) and were younger (59.5 vs 63.4 years, p=0.009) compared to the 82 patients who dropped out.
MIO
At baseline, as part of the inclusion criteria, no patients suffered from trismus (n = 211). At 1 year post-RT, however, a total of 27% (n = 49) met the trismus criterion, and at 5 years after finishing RT, the corresponding figure was 28% (n = 36, Table 2).
Table 2.
MIO at pre-radiotherapy, 1 and 5 years post-radiotherapy for patients with and without trismus (mean (95% CI))
| Pre-RT | 1 year post-RT | 5 years post-RT | |||||
|---|---|---|---|---|---|---|---|
| No trismus (n = 211) | Trismus (n = 49) | No trismus (n = 131) | P value | Trismus (n = 36) | No trismus (n = 93) | P value | |
| Mean (95% CI) | Mean (95% CI) | Mean (95% CI) | Mean (95% CI) | Mean (95% CI) | |||
| MIO | 51.5 (51–52) | 31.3 (30–33) | 45.5 (44–47) | < 0.001 | 30.4 (29–32) | 45.5 (44–47) | < 0.001 |
Abbreviations: MIO maximum interincisal opening, RT radiotherapy, CI confidence interval
EORTC QLQ C30 and HN35
Results from the EORTC QLQ-C30 are presented in Table 3. The patients in the trismus group scored significantly worse compared to the patients with no trismus on eight of 15 domains at 1 year post-RT. The domains in question were physical, role, and social function, as well as global quality of life, fatigue, pain, appetite loss, and financial loss. At 5 years post-RT, patients suffering from trismus reported significantly worse scores in 11 out of 15 domains. This included most functional and all symptom items, as well as the single items dyspnea, appetite loss, and financial loss.
Table 3.
EORTC QLQ C30 at pre-radiotherapy, 1 and 5 years post-radiotherapy for patients with and without trismus (mean (95% CI))
| Pre-RT | 1 year post-RT | 5 years post-RT | |||||
|---|---|---|---|---|---|---|---|
| No trismus (n = 211) | Trismus (n = 49) | No trismus (n = 131) | P value | Trismus (n = 36) | No trismus (n = 93) | P value | |
| Mean (95% CI) | Mean (95% CI) | Mean (95% CI) | Mean (95% CI) | Mean (95% CI) | |||
| Functioning domains | |||||||
| Physical function | 89.7 (87–92) | 81.9 (77–87) | 88.5 (86–91) | 0.03 | 81.4 (74–89) | 84.9 (81–89) | 0.42 |
| Role function | 74.2 (70–79) | 65.6 (56–75) | 82.5 (78–87) | < 0.001 | 70.6 (59–82) | 85.9 (81–91) | 0.01 |
| Emotional function | 70.1 (67–73) | 76.2 (69–84) | 83.6 (80–87) | 0.06 | 76.0 (67–85) | 87.1 (83–91) | < 0.01 |
| Cognitive function | 85.0 (83–88) | 81.3 (75–88) | 86.4 (83–90) | 0.14 | 74.5 (65–84) | 87.1 (84–90) | < 0.01 |
| Social function | 82.9 (80–86) | 71.8 (63–81) | 84.0 (80–88) | < 0.01 | 73.0 (63–83) | 87.4 (83–92) | < 0.01 |
| Global quality of life | 65.8 (63–69) | 62.8 (56–70) | 71.3 (68–75) | 0.02 | 61.0 (51–71) | 75.5 (71–80) | < 0.01 |
| Symptom scales | |||||||
| Fatigue | 23.0 (20–26) | 32.2 (25–40) | 23.8 (20–28) | 0.04 | 36.6 (23–50) | 20.5 (16–26) | < 0.01 |
| Nausea/vomiting | 4.6 (3–6) | 6.8 (3–11) | 3.6 (2–6) | 0.14 | 8.8 (2–16) | 2.5 (1–5) | 0.03 |
| Pain | 23.7 (20–27) | 24.1 (16–32) | 15.2 (12–19) | 0.03 | 31.4 (19–43) | 12.3 (8–17) | < 0.001 |
| Single items | |||||||
| Dyspnoea | 15.5 (12–19) | 22.4 (15–30) | 15.6 (12–19) | 0.08 | 32.3 (22–43) | 15.8 (11–20) | < 0.01 |
| Insomnia | 27.9 (24–32) | 21.2 (12–30) | 18.7 (14–24) | 0.61 | 27.5 (16–39) | 20.9 (15–27) | 0.27 |
| Appetite loss | 12.9 (10–16) | 31.3 (21–42) | 14.9 (10–20) | < 0.01 | 17.6 (9–26) | 6.5 (3–10) | 0.01 |
| Constipation | 8.5 (6–11) | 10.9 (5–17) | 9.52 (6–13) | 0.68 | 14.7 (5–25) | 8.7 (5–12) | 0.17 |
| Diarrhoea | 4.3 (3–6) | 5.44 (1–10) | 5.11 (2–8) | 0.87 | 6.9 (2–15) | 5.2 (2–8) | 0.61 |
| Financial loss | 13.5 (10–17) | 24.5 (15–34) | 14.0 (9–19) | 0.03 | 17.6 (7–28) | 7.0 (3–11) | 0.03 |
Abbreviations: RT radiotherapy, CI confidence interval
Scores range from 0 to 100. Higher scores in the function domains and global quality of life indicate better function, whereas higher scores in symptom domains indicate increased symptom burden
Patients with trismus also reported worse symptoms compared to those without trismus in the EORTC QLQ HN35-variables speech, teeth, and mouth opening at 1 year post-treatment completion. The same variables also appeared significantly worse in the trismus group at the 5-year follow-up in addition to other variables, including pain, senses, social eating, dry mouth, sticky saliva, and feeling ill. The items where both groups reported the highest symptom burden at both follow-up timepoints were dry mouth and sticky saliva. The results from EORTC QLQ-HN35 are presented in Table 4.
Table 4.
EORTC QLQ HN35 at pre-radiotherapy, 1 and 5 years post-radiotherapy for patients with and without trismus (mean (95% CI))
| Pre-RT | 1 year post-RT | 5 years post-RT | |||||
|---|---|---|---|---|---|---|---|
| No trismus (n = 211) | Trismus (n = 49) | No trismus (n = 131) | P value | Trismus (n = 36) | No trismus (n = 93) | P value | |
| Mean (95% CI) | Mean (95% CI) | Mean (95% CI) | Mean (95% CI) | Mean (95% CI) | |||
| Symptom domains | |||||||
| Pain | 21.9 (19–25) | 26.0 (19–33) | 21.4 (18–25) | 0.21 | 28.3 (19–38) | 13.0 (9–17) | < 0.001 |
| Swallowing | 14.4 (11–17) | 25.5 (19–32) | 19.4 (15–23) | 0.12 | 25.0 (15–36) | 16.2 (12–21) | 0.08 |
| Senses | 9.1 (7–12) | 27.9 (21–35) | 30.3 (25–35) | 0.61 | 31.0 (22–40) | 18.2 (13–23) | 0.02 |
| Speech | 12.3 (10–15) | 22.3 (16–28) | 12.6 (10–16) | < 0.01 | 23.2 (14–32) | 10.4 (7–14) | < 0.01 |
| Social eating | 13.2 (10–16) | 34.0 (27–42) | 23.8 (19–30) | 0.05 | 27.5 (18–37) | 14.2 (10–19) | < 0.01 |
| Social contact | 7.1 (5–10) | 12.9 (8–18) | 7.3 (4–10) | 0.06 | 14.1 (6–22) | 7.1 (4–10) | 0.06 |
| Sexuality | 28.3 (23–33) | 38.5 (28–49) | 28.8 (23–35) | 0.10 | 33.3 (22–45) | 32.9 (25–41) | 0.95 |
| Symptom single items | |||||||
| Teeth | 7.5 (5–10) | 27.2 (17–37) | 16.8 (12–21) | 0.04 | 34.3 (22–47) | 17.8 (11–24) | 0.02 |
| Open mouth | 8.7 (6–12) | 42.2 (33–51) | 15.5 (12–19) | < 0.001 | 47.6 (36–60) | 12.5 (8–17) | < 0.001 |
| Dry mouth | 18.1 (14–22) | 72.8 (64–81) | 62.9 (57–69) | 0.06 | 66.7 (56–78) | 51.6 (45–59) | 0.02 |
| Sticky saliva | 16.5 (13–20) | 53.5 (44–63) | 54.2 (48–61) | 0.90 | 62.7 (43–82) | 38.8 (31–46) | < 0.01 |
| Cough | 16.9 (14–20) | 19.0 (12–26) | 21.6 (17–27) | 0.58 | 30.5 (19–42) | 19.8 (14–25) | 0.07 |
| Felt ill | 18.3 (15–22) | 19.4 (12–27) | 14.1 (10–19) | 0.22 | 22.9 (13–33) | 7.7 (4–11) | < 0.01 |
| Nutritional supplement | 12.5 (8–17) | 32.7 (19–46) | 18.9 (12–26) | 0.06 | 25.7 (11–41) | 13.2 (6–20) | 0.10 |
Abbreviations: RT radiotherapy, CI confidence interval
Scores range from 0 to 100. Higher scores in symptom domains indicate increased symptom burden
GTQ
The patients in the trismus group reported significantly more symptoms in all three GTQ domains (jaw-related problems, eating limitations, and muscular tension) at 5 years post-RT. At 1 year after RT completion, every symptom except for experiencing facial pain right now was statistically significantly worse in the trismus group. The GTQ results are presented in Table 5.
Table 5.
GTQ at pre-radiotherapy, 1 and 5 years post-radiotherapy for patients with and without trismus (mean (95% CI))
| Pre-RT | 1 year post-RT | 5 years post-RT | |||||
|---|---|---|---|---|---|---|---|
| No trismus (n = 211) | Trismus (n = 49) | No trismus (n = 131) | P value | Trismus (n = 36) | No trismus (n = 96) | P value | |
| Mean (95% CI) | Mean (95% CI) | Mean (95% CI) | Mean (95% CI) | Mean (95% CI) | |||
| Domains | |||||||
| Jaw-related problems | 9.6 (7–12) | 38.9 (33–45) | 18.8 (15–23) | < 0.001 | 46.0 (37–55) | 13.1 (9–17) | < 0.001 |
| Eating limitations | 11.7 (8–15) | 36.7 (30–44) | 22.3 (18–27) | < 0.001 | 41.4 (33–50) | 18.5 (13–24) | < 0.001 |
| Muscular tension | 7.0 (5–9) | 28.7 (23–35) | 13.5 (11–16) | < 0.001 | 36.9 (31–43) | 17.8 (13–23) | < 0.001 |
| Single items | |||||||
| Facial pain | |||||||
| Right now | 9.2 (7–12) | 16.7 (11–22) | 11.0 (8–14) | 0.07 | 23.8 (16–32) | 7.1 (4–10) | < 0.001 |
| Pain when worst last month | 22.3 (19–26) | 27.2 (20–34) | 16.5 (13–20) | < 0.01 | 28.6 (19–38) | 9.2 (6–13) | < 0.001 |
| Pain average | 18.7 (16–22) | 26.9 (20–34) | 15.0 (12–19) | < 0.01 | 28.6 (20–37) | 7.7 (5–11) | < 0.001 |
| Pain interfering with social, leisure, and family activities | 6.4 (4–9) | 15.1 (9–22) | 5.8 (3–8) | < 0.01 | 27.1 (16–38) | 4.1 (1–7) | < 0.001 |
| Pain affecting ability to work last month | 9.4 (6–13) | 16.8 (9–25) | 6.6 (3–10) | < 0.01 | 23.6 (14–33) | 2.8 (1–5) | < 0.001 |
| LOM | 8.3 (6–11) | 42.7 (36–50) | 17.5 (13–22) | < 0.001 | 42.9 (34–52) | 14.3 (10–19) | < 0.001 |
| LOM interfering with social, leisure, and family activities | 4.1 (2–6) | 22.9 (15–30) | 6.0 (4–9) | < 0.001 | 25.7 (16–35) | 5.6 (2–9) | < 0.001 |
| LOM affecting ability to work | 4.4 (2–7) | 20.3 (13–28) | 6.9 (4–10) | < 0.001 | 24.3 (14–34) | 3.3 (1–6) | < 0.001 |
Abbreviations: LOM limitations in mouth opening, RT radiotherapy, CI confidence interval. The scores of the domains and single items range from 0 to 100, where a higher score indicates more symptoms
Discussion
This study is, to the best of our knowledge, the longest follow-up study describing HRQL in HNC patients with post-RT trismus. Its large prospective cohort of patients and longitudinal design has yielded important findings in terms of HRQL prevalence and trismus-related symptoms.
Firstly, the trend that patients suffering from trismus report generally worse HRQL scores compared to those without trismus is in line with previous findings of shorter-term studies, but highlights that these deteriorations persist long term [10, 20, 21]. The longer follow-up period in this study further revealed interesting findings as the disadvantageous scoring persisted at 5 years post-RT. In addition, more HRQL and pain domains displayed statistically significant deteriorations compared to at 12 months post-RT. The prevalence of trismus remained fairly constant at 27–28% between the 12-month and 5-year follow-up and, hence, cannot explain the continued deterioration reported in HRQL. The endpoint deterioration seen in the EORTC QLQ HN35 domains, senses, sticky saliva, and dry mouth, could, however, be attributed to the development of late radiation-induced effects [22]. Epstein et al. [23] concluded that both fraction size, treatment time, and radiated tissue volume impacted the development of mucositis, and Schultz et al. [24] found a 78% incidence of hyposalivation in their 88 patients, where higher radiation doses increased the risk of xerostomia four-fold. Hence, other factors influenced by tumor site, treatment type, and dosage of RT also impact HRQL.
Other aspects known to contribute to HRQL might be found in the patient characteristics. Patients who live alone have been found more likely to report a negative impact on quality of life [25, 26]. Even though there was no statistically significant difference in the present study at 5 years post-RT, a total of 33% of the participants with trismus reported living alone, whereas the corresponding number among the participants without trismus was 19%. This could be a contributing factor to the differences found in the domains social function and global quality of life. In a survey study by Dahill et al. [27], loneliness after HNC treatment was associated with a worse overall quality of life. The study was however limited by a low response rate and insufficient information about for example marital status and living alone or not. Research regarding patients with HNC and partner/spousal support or methods for coping is still modestly conducted. A cross-sectional study on cancer patients by Sayilan et al. showed married individuals to have better social support levels than single individuals [28]. Additionally, the presence of comorbidities and a higher tumor stage have been associated with worse HRQL, where a somewhat larger, although not statistically significant, extent of the participants with trismus had more advanced disease and more comorbidities [26].
Additional important findings in this material highlighted that the trismus group reported worse scores with regard to all pain modules in the EORTC QLQ-HN35 and the GTQ compared to those without trismus. Scores continued to deteriorate over time for patients with trismus, whereas on the other hand, the quantitative scores for patients without trismus improved at the 5-year follow-up. Thus, a statistically significant pattern regarding pain emerges over time, which appears disadvantageous for those suffering from trismus. These results are in line with a previous study regarding pain and its association with trismus, where structured exercise aiming to improve jaw-opening also resulted in reduced pain 3 years following oncologic treatment. This indicates that trismus is a prominent reason for post-RT pain [12]. Interestingly, the majority of domains and items in both the EORTC QLQ-C30 and QLQ-HN35 improved to match or surpass scores reported at baseline for patients without trismus at the 5-year follow-up.
Overall, the findings in this study highlight and further confirm the presence and persistence of long-term trismus, trismus-specific symptoms, and deteriorations in HRQL for those suffering from the condition. Previous research has demonstrated that patients who perform structured jaw exercises also report less trismus and better scoring regarding HRQL. A prospective interventional study by Karlsson et al. reported on 100 HNC patients with trismus of which 50 underwent a 10-week structured exercise program and the remaining constituted a control group. Patients were followed up to 3 years post-RT, and at all study timepoints, MIO was higher for the intervention group along with better reported HRQL scores [29]. Furthermore, a separate study by Pauli et al. concluded that HNC patients who experienced jaw-related pain prior to oncologic treatment were at higher risk of developing radiation-induced trismus after 6 months compared to those without jaw-related pain, thus highlighting the important of optimizing patients’ pain treatment and oral health even before starting radiation treatment [30].
Clinical implications
As it is now known that trismus is a long-term complication severely affecting HRQL and that structured jaw training improves MIO, the importance of routinely introducing rehabilitative measures should continue to be emphasized. However, more recent studies have also focused on prophylactic intervention. A recent systematic review by Wang et al. covering prehabilitative interventions for trismus prevention identified a total of 11 studies, of which six contained sufficient information for analysis [31]. Results are promising both in terms of MIO and HRQL, yet all studies were severely hampered by small study sizes, short-term follow-up of a maximum of 2 years as well as a varying range of implemented intervention modalities, often lacking an objective MIO-measure and thereby resulting in low confidence ratings. Thus, studies investigating prehabilitative trismus strategies long-term should also be conducted.
Strengths and limitations
The strength of this study lies in its prospective, longitudinal design and in the size of the cohort. Furthermore, objective measurements have been used for MIO, and patient-reported outcome data have been obtained through validated, reliable, and widely used HRQL instruments. The study is limited by the patients who dropped out as these were in slightly worse overall health at baseline, raising the awareness of survival bias in long-term studies. Another further possible limitation includes the period that the data was collected. Since then, treatment methods and regimens have somewhat changed which may lead to an altered prevalence of post-RT trismus and hence associated HRQL data.
Conclusion
This study highlights that HNC patients suffering from post-RT trismus report worse HRQL and trismus-specific symptoms compared to patients not suffering from post-RT trismus. These differences not only persist but increase up to at least 5 years following treatment completion. The results from the study highlight that RT-induced trismus affects long-term HRQL, jaw symptoms, and pain, further stressing the need for intervention in this patient group.
Author contribution
Caterina Finizia is mainly responsible for study conception and design. Material preparation, data collection, and analysis were performed by Susan Aghajanzadeh, Therese Karlsson, and Lisa Tuomi. The first draft of the manuscript was written by Therese Karlsson and Susan Aghajanzadeh, and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.
Funding
Open access funding provided by University of Gothenburg. This work was supported by the Swedish Cancer Society (grant no. 19 0296 Pj), the Research and Development Council (FoU), Region Västra Götaland, Sweden (grant no. VGRFOUREG-967550), The Assar Gabrielsson Foundation Sweden (grant no. FB20-86), and the Medical Faculty of Gothenburg University Sweden (grant no. ALFGBG-428761).
Declarations
Ethics approval
The study was conducted according to the Declaration of Helsinki and was approved by the Regional Ethic Review Board in Gothenburg, Sweden.
Consent to participate
Written informed consent was obtained from all participants included in the study.
Consent for publication
Not relevant.
Conflict of interest
The authors declare no competing interests.
Footnotes
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
References
- 1.Väst RC. Huvud- och halscancer: Årsrapport Nationellt Kvalitetsregister. 2021. [Google Scholar]
- 2.Väst RC. Nationellt vårdprogram Huvud- och halscancer. 2019. [Google Scholar]
- 3.Deschler DG, Richmon JD, Khariwala SS, et al. The “new” head and neck cancer patient-young, nonsmoker, nondrinker, and HPV positive: evaluation. Otolaryngol Head Neck Surg. 2014;151(3):375–380. doi: 10.1177/0194599814538605. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Young D, Xiao CC, Murphy B, et al. Increase in head and neck cancer in younger patients due to human papillomavirus (HPV) Oral Oncol. 2015;51(8):727–730. doi: 10.1016/j.oraloncology.2015.03.015. [DOI] [PubMed] [Google Scholar]
- 5.Kamstra JI, Dijkstra PU, van Leeuwen M, et al. Mouth opening in patients irradiated for head and neck cancer: a prospective repeated measures study. Oral Oncol. 2015;51(5):548–555. doi: 10.1016/j.oraloncology.2015.01.016. [DOI] [PubMed] [Google Scholar]
- 6.Johnson J, van As-Brooks CJ, Fagerberg-Mohlin B, et al. Trismus in head and neck cancer patients in Sweden: incidence and risk factors. Med Sci Monit. 2010;16(6):Cr278–Cr282. [PubMed] [Google Scholar]
- 7.Pauli N, Johnson J, Finizia C, et al. The incidence of trismus and long-term impact on health-related quality of life in patients with head and neck cancer. Acta Oncol. 2013;52(6):1137–1145. doi: 10.3109/0284186X.2012.744466. [DOI] [PubMed] [Google Scholar]
- 8.Dijkstra PU, Huisman PM, Roodenburg JL. Criteria for trismus in head and neck oncology. Int J Oral Maxillofac Surg. 2006;35(4):337–342. doi: 10.1016/j.ijom.2005.08.001. [DOI] [PubMed] [Google Scholar]
- 9.van der Geer SJ, van Rijn PV, Roodenburg JLN, et al. Prognostic factors associated with a restricted mouth opening (trismus) in patients with head and neck cancer: systematic review. Head Neck. 2020;42(9):2696–2721. doi: 10.1002/hed.26327. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Johnson J, Johansson M, Rydén A, et al. Impact of trismus on health-related quality of life and mental health. Head Neck. 2015;37(11):1672–1679. doi: 10.1002/hed.23816. [DOI] [PubMed] [Google Scholar]
- 11.Louise Kent M, Brennan MT, Noll JL, et al. Radiation-induced trismus in head and neck cancer patients. Support Care Cancer. 2008;16(3):305–309. doi: 10.1007/s00520-007-0345-5. [DOI] [PubMed] [Google Scholar]
- 12.Andrell PKT, Karlsson O, Aghajanzadeh S, Finizia C. Structured jaw exercise in head and neck cancer survivors with trimus greatly increases chance of being pain free 3-years after oncologic treatment. J Cancer Sci Clin Ther. 2020;4(4):557–573. doi: 10.26502/jcsct.5079095. [DOI] [Google Scholar]
- 13.Piccirillo JF, Feinstein AR. Clinical symptoms and comorbidity: significance for the prognostic classification of cancer. Cancer. 1996;77(5):834–842. doi: 10.1002/(SICI)1097-0142(19960301)77:5<834::AID-CNCR5>3.0.CO;2-E. [DOI] [PubMed] [Google Scholar]
- 14.Kaplan MH, Feinstein AR. The importance of classifying initial co-morbidity in evaluating the outcome of diabetes mellitus. J Chronic Dis. 1974;27(7-8):387–404. doi: 10.1016/0021-9681(74)90017-4. [DOI] [PubMed] [Google Scholar]
- 15.UICC . TNM Classification of malignant tumours. 7 2009. [Google Scholar]
- 16.Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85(5):365–376. doi: 10.1093/jnci/85.5.365. [DOI] [PubMed] [Google Scholar]
- 17.Bjordal K, Hammerlid E, Ahlner-Elmqvist M, et al. Quality of life in head and neck cancer patients: validation of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-H&N35. J Clin Oncol. 1999;17(3):1008–1019. doi: 10.1200/JCO.1999.17.3.1008. [DOI] [PubMed] [Google Scholar]
- 18.Fayers PMMD. Quality of life: the assessment, analysis ad interpretation of patient-reported outcomes. New York: Wiley; 2007. [Google Scholar]
- 19.Johnson J, Carlsson S, Johansson M, et al. Development and validation of the Gothenburg Trismus Questionnaire (GTQ) Oral Oncol. 2012;48(8):730–736. doi: 10.1016/j.oraloncology.2012.02.013. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Lee LY, Chen SC, Chen WC, et al. Postradiation trismus and its impact on quality of life in patients with head and neck cancer. Oral Surg Oral Med Oral Pathol Oral Radiol. 2015;119(2):187–195. doi: 10.1016/j.oooo.2014.10.003. [DOI] [PubMed] [Google Scholar]
- 21.Jia Z, Li J, Harrison C et al (2021) Association of trismus with quality of life and swallowing in survivors of head and neck cancer. Otolaryngol Head Neck Surg:1945998211026848 [DOI] [PubMed]
- 22.O'Sullivan B, Levin W. Late radiation-related fibrosis: pathogenesis, manifestations, and current management. Semin Radiat Oncol. 2003;13(3):274–289. doi: 10.1016/S1053-4296(03)00037-7. [DOI] [PubMed] [Google Scholar]
- 23.Epstein JB, Thariat J, Bensadoun RJ, et al. Oral complications of cancer and cancer therapy: from cancer treatment to survivorship. CA Cancer J Clin. 2012;62(6):400–422. doi: 10.3322/caac.21157. [DOI] [PubMed] [Google Scholar]
- 24.Schulz RE, Bonzanini LIL, Ortigara GB et al (2021) Prevalence of hyposalivation and associated factors in survivors of head and neck cancer treated with radiotherapy. J Appl Oral Sci 29:e20200854 [DOI] [PMC free article] [PubMed]
- 25.Dieperink KB, Hansen S, Wagner L, et al. Living alone, obesity and smoking: important factors for quality of life after radiotherapy and androgen deprivation therapy for prostate cancer. Acta Oncol. 2012;51(6):722–729. doi: 10.3109/0284186X.2012.682627. [DOI] [PubMed] [Google Scholar]
- 26.Østhus AA, Aarstad AK, Olofsson J, et al. Comorbidity is an independent predictor of health-related quality of life in a longitudinal cohort of head and neck cancer patients. Eur Arch Otorhinolaryngol. 2013;270(5):1721–1728. doi: 10.1007/s00405-012-2207-0. [DOI] [PubMed] [Google Scholar]
- 27.Dahill A, Al-Nakishbandi H, Cunningham K, et al. Loneliness and quality of life after head and neck cancer. Br J Oral Maxillofac Surg. 2020;58(8):959–965. doi: 10.1016/j.bjoms.2020.04.041. [DOI] [PubMed] [Google Scholar]
- 28.Aydın Sayılan A, Demir DM. Illness perception, perceived social support and quality of life in patients with diagnosis of cancer. Eur J Cancer Care (Engl) 2020;29(4):e13252. doi: 10.1111/ecc.13252. [DOI] [PubMed] [Google Scholar]
- 29.Karlsson O, Karlsson T, Pauli N, et al. Jaw exercise therapy for the treatment of trismus in head and neck Cancer: a prospective three-year follow-up study. Support Care Cancer. 2021;29(7):3793–3800. doi: 10.1007/s00520-020-05517-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30.Pauli N, Fagerberg Mohlin B, Mejersjö C, et al. Temporomandibular disorder as risk factor for radiation-induced trismus in patients with head and neck cancer. Clin Exp Dent Res. 2022;8(1):123–129. doi: 10.1002/cre2.511. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31.Wang Y-H, Huang Y-A, Chen I-H. Healthcare. MDPI; 2022. Exercise for trismus prevention in patients with head and neck cancer: a network meta-analysis of randomized controlled trials. [DOI] [PMC free article] [PubMed] [Google Scholar]